Dr. Miguel de la Garza, President of the Florida Society of Interventional Pain Physicians and Renowned Physician at Surgery Partners, Adopts Milestone Scientific’s CompuFlo® Epidural Instrument for Pain Management – Yahoo Finance

Read Time:10 Minute, 36 Second

New weekly jobless claims ticked up slightly last week to hold near a 52-year low.

Marks important step in planned expansion of the CompuFlo Epidural instrument into the pain management market
ROSELAND, N.J., Dec. 01, 2021 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that Dr. Miguel de la Garza has begun incorporating the CompuFlo® Epidural instrument into his practice for pain management, following approval by Surgery Partners, one of the largest and growing surgical services business in the country. Dr. de la Garza plans to utilize the CompuFlo Epidural instrument for both surgical cases and office based procedures to safely and quickly access the epidural space.

Dr. de la Garza, a recognized expert in pain management, is the current president of the Florida Society of Interventional Pain Physicians, which is one of the largest pain societies in the United States, representing 400 interventional pain management specialists in the state of Florida. Dr. de la Garza trained at the prestigious Cleveland Clinic for his fellowship and has published numerous articles and lectured internationally. He is a partner at Comprehensive Pain Management Partners in Tampa, Florida, and performs his clinical pain management procedures at Surgery Partners. Founded in 2004, Surgery Partners has over 4,000 affiliated physicians, and more than 180 locations in 31 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities.
Dr. de la Garza commented, “Milestone’s CompuFlo® Epidural instrument represents the future of anesthesiology and pain management. The instrument is easy to use, and I wanted to secure this product to decrease the chance of intrathecal punctures, as I believe it will increase safety for a number of procedures. I strongly recommend this instrument to other practitioners in the pain management field.”
Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We appreciate the support of Dr. Miguel de la Garza who is a leader in the field of pain management. We’re also pleased to announce that Surgery Partners has approved the CompuFlo Epidural instrument for use across their network in pain management. Our initial focus has been on the labor and delivery market with 2.4 million annual epidural analgesia procedures in the U.S. alone, where our sales pipeline is solid and growing, and we are in advanced discussions with hospitals and larger health care institutions. Nevertheless, this latest agreement marks a major step in our goal of expanding the addressable market for our instruments beyond labor and delivery. The overall addressable market for epidural anesthesia is estimated to be approximately $5 billion, with 11 million epidural procedures performed in the U.S. on an annual basis. The pain management market is at least twice the size of the labor and delivery market segment, and we believe the CompuFlo® Epidural instrument has the potential to capture a significant share of this market given its unparalleled safety, reduced risk of complications and cost savings.”
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2020. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact: David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: [email protected]
Tel: 212-671-1020

Inovio (INO) made a big splash last year with its Covid-19 DNA vaccine candidate INO-4800. Development, however, has been slow, and the vaccine is still a while away from entering the market, should it ever get that far. In the meantime, Inovio has been working on other, less headline grabbing candidates in its pipeline. On Tuesday, Inovio provided an update from the development of the Phase 3 program for VGX-3100, indicated to treat HPV-associated cervical high-grade squamous intraepithelial le
Is AbbVie stock a buy as shares retake their key moving averages on strong third-quarter earnings? Is ABBV stock a buy right now?
Investors are always on the lookout for untapped opportunities. Looking at the case for BioCryst Pharmaceuticals (BCRX), Oppenheimer’s Justin Kim thinks that the biotech fits the bill, calling it an “underappreciated commercial-stage company with pipeline growth potential.” At the heart of Kim’s thesis lies Orladeyo, the biotech’s treatment for the prevention of hereditary angioedema (HAE) attacks, which was granted FDA approval in December 2020. Characterized by unpredictable and possibly life-
Shares of Biogen Inc. gained 0.9% in premarket trading on Thursday after the company said it plans to submit a protocol for a Phase 4 confirmatory study for its Alzheimer's disease drug to U.S. regulators in March. The study is a condition of the accelerated approval granted to Aduhelm last year. It is expected to enroll 1,300 participants, dose the first patient in May, and to take about four years. Biogen's stock is down 3.6% for the year, while the broader S&P 500 has gained 25.4%.
Is Pfizer stock a buy after a new Covid variant emerged that partially eludes protection from its Covid shot? Is PFE stock a buy right now?
Shares of Alzamend Neuro (NASDAQ: ALZN) surged 28% on Tuesday, as investors bought in ahead of the biotech's upcoming clinical data release for its experimental Alzheimer's treatment. Alzamend is an early stage biopharmaceutical company focused on creating therapies for neurodegenerative diseases and psychiatric conditions. Its investigational oral treatment for dementia related to Alzheimer's, AL001, has been shown to prevent cognitive impairment in mice. Alzamend is currently conducting a phase 1 human clinical study to evaluate the safety and proper dosing for AL001 in a planned phase 2 trial.
A new private study by South Africa’s Discovery Health suggests that Pfizer Inc (NYSE: PFE) and BioNTech SE’s (NASDAQ: BNTX) COVID-19 vaccine is just 33% effective against infections by the omicron variant. However, the Company reported that the variant appears to cause less severe disease. Based on 211,000 positive COVID-19 cases, the data showed that the risk of hospitalization was 29% lower than in South Africa’s first wave back in mid-2020. The Pfizer/BioNTech shot was 70% effective at preve
Former Biden Transition COVID Advisory Board member Dr. Julie Morita joins Yahoo Finance Live to discuss Omicron as well as the demands for booster shots and vaccines. She also mentions that Americans are not out of the woods yet as we head into the holiday season.
Is Merck stock a buy or sell after its Covid pill, molnupiravir, passed muster with FDA advisors? Is MRK stock a buy or sell right now?
With the World Health Organisation listing Omicron as a 'variant of concern,' and the UK tightening COVID-19 measures, we ask: what are the symptoms of Omicron?
Shares of Eli Lilly (NYSE: LLY) were jumping 8.3% as of 11:48 a.m. ET on Wednesday. Lilly announced that it has initiated a rolling submission to the Food and Drug Administration for pirtobrutinib in treating mantle cell lymphoma. It also released new biomarker data showing positive efficacy for donanemab in treating Alzheimer's disease. Both ranges are well above consensus estimates.
U.S. workers with severe cases of COVID-19 may be covered by a law prohibiting disability discrimination in the workplace, while milder cases would not qualify, according to guidance issued on Tuesday by the agency that enforces the law. The Equal Employment Opportunity Commission (EEOC) in the guidance posted on its website said COVID-19 cases that persist for more than a few weeks, and impairments caused by the illness, can be considered "disabilities" under the Americans with Disabilities Act (ADA). The ADA protects workers from being fired or facing retaliation because of their disabilities. The law also requires employers to offer reasonable accommodations that would allow workers with disabilities to do their jobs.
Health: U.S. COVID death toll tops 800,000 — Fighting COVID misinformation with cartoons — Biden admin orders enough Pfizer antiviral pills for 10 million Americans.Vaccines: COVID booster gap traps millions of Americans — Millions of America's seniors are vulnerable to Omicron.States: Colorado governor says COVID "medical emergency" is over — Supreme Court declines to block NY's COVID vaccine mandate for health care workersWorld: COVID vaccine passports boost uptake in countries with lower cove
How do you tell if you've contracted COVID-19, or is it the flu or allergies? It can be tricky, but here are some guidelines.
Indonesian President Joko Widodo urged people and government officials to refrain from traveling abroad after the country detected its first case of the omicron variant of the coronavirus in a cleaning worker at a hospital in Jakarta. The patient has no symptoms and is being quarantined at the Athlete’s Village emergency hospital, where the person worked. Indonesia’s Health Minister Budi Gunadi Sadikin said the infection was confirmed on Wednesday, and he urged people to continue following recommended protocols, including wearing masks and maintaining physical distance.
Nurse sharks gliding around a tank at the University of Wisconsin-Madison may hold the secret to an unusual treatment for COVID-19, according to a new study in the journal Nature Communications.
In the fifth class of our restorative yoga series, our instructor Rita Murjani leads you through 40 minutes of beginner-friendly poses for twisting your spine and sacrum – incorporating knees-to-chest, half-twists, and supine pigeon. Rita Murjani teaches at SkyTing Yoga and Equinox in NYC and is the Head of Mindfulness + Strategy at Aduri, a mindful living brand. Inspired by Katonah Yoga® and her Indian heritage, she left her work in investment banking to become a leader in the yoga and mental wellbeing space. *The Sanskrit translations featured in this video have been verified by Priya Patel from Brown University, however usage of these terms can vary across the global yoga community.
(Bloomberg) — France is imposing tougher rules on people arriving from the U.K., including a requirement to self-isolate, to slow the spread of Covid-19’s omicron variant. The measures are introduced after new daily cases in the U.K. rose to a record. Most Read from BloombergCan Indoor Farms Reach Skyscraper Height?Saudi Arabia Wants Its Capital to Be Somewhere You’d Want to LiveZero Taxes, Golf and Beach Houses Create a Crypto Island ParadiseThe rise in infections is hitting economic activity
Eli Lilly on Wednesday forecast 2022 profit above Wall Street estimates as it bets on new drug approvals to counter the impact of competition and pricing pressures on its other key treatments, sending its shares up nearly 10%. The company has plans to launch five more medicines over the next two years, including diabetes drug tirzepatide and Alzheimer's disease treatment donanemab, helping it meets its target of launching 20 new medicines over a 10-year period through 2023, Lilly said.
Americans feel ‘worn out’ by impact of virus in daily lives and changes they have had to make

source

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

6 thoughts on “Dr. Miguel de la Garza, President of the Florida Society of Interventional Pain Physicians and Renowned Physician at Surgery Partners, Adopts Milestone Scientific’s CompuFlo® Epidural Instrument for Pain Management – Yahoo Finance

  1. I was just searching for this information for a while. After 6 hours of continuous Googleing, finally I got it in your website. I wonder what is the lack of Google strategy that don’t rank this type of informative sites in top of the list. Usually the top web sites are full of garbage.

  2. Youre so cool! I dont suppose Ive learn anything like this before. So good to search out any individual with some unique ideas on this subject. realy thank you for beginning this up. this website is something that is needed on the web, someone with a bit of originality. useful job for bringing something new to the internet!

  3. This is really interesting, You are a very skilled blogger. I have joined your rss feed and look forward to seeking more of your magnificent post. Also, I’ve shared your website in my social networks!

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Brandywine and Jennersville Hospitals will close, leaving thousands in Chester County without nearby emergency care – The Philadelphia Inquirer
Next post Recommended Initial Treatments for Infantile Spasms Are Superior to Non-Standard Therapies – Weill Cornell Medicine Newsroom
Close